ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis

Rheumatology (Oxford). 2016 Jan;55(1):80-8. doi: 10.1093/rheumatology/kev267. Epub 2015 Aug 27

To assess the impact of achieving Assessment in SpondyloArthritis international Society 40% (ASAS40) response or an Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID) state on patient-reported outcomes (PROs) among patients with non-radiographic axial SpA (nr-axSpA).

View abstract


Van der Heijde D, Joshi A, Pangan AL, Chen N, Betts KA, Mittal M, Bao Y.